Edesa Biotech, Inc.

EDSA Healthcare Biotechnology

In the quarter to June 2026, EPS fell 140.0% and free cash flow fell 81.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.57 0.10 −3.75%
Market cap
$36.1M
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
3/9
Altman Z
22.29
Beneish M
−4.36
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
10.60 16.51 4.67 2.70
Current Ratio
10.67 16.82 4.76 2.76
Net Debt/EBITDA
4.42 5.20 2.34 1.88
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.77 0.93 0.48 0.57
Capex/Depreciation
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.15 0.13 0.16 0.15
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.30) (0.26) (0.24) (0.34)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.30) (0.26) (0.24) (0.34)
Cash per Share
1.90 1.51 1.17 1.15
Shareholders Equity per Share
2.19 1.75 1.19 0.98
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
2.19 1.75 1.19 0.98
Free Cash Flow
(1.72) (2.09) (2.02) (3.08)
Working Capital
10.43 11.96 8.23 6.87
Net Current Asset Value
10.43 11.96 8.23 6.87
Other line items
Average Receivables
0.46 0.39 0.30 0.26
Average Payables
1.45 1.33 1.55 2.29
Average Assets
8.67 9.44 14.42 13.76
Average Common Equity
2.59 2.97 4.09 2.65

Fold the line items

Columns are period end dates